Breast Cancer

While progression-free survival was similar, overall survival was better in CDK4/6 inhibitor combinations as first-line therapy followed by everolimus combinations and chemotherapy.

Across the MONALEESA-2, -3, and -7 clinical trials, first-line treatment with endocrine therapy and ribociclib mitigated negative effects on quality of life, global health scores, pain, and emotional functioning.

Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative, endocrine-sensitive, advanced breast cancer.

In addition to the significant benefit observed in the MONARCH 2 study across first- and second-line treatment, marked effects were observed in patients with less encouraging prognostic indicators.

In this real-world retrospective study, more patients in the ribociclib cohort compared with palbociclib and abemaciclib maintained starting doses and fewer patients decreased to 50% of the starting dose.

Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib.

Bret Miller is a 10-year breast cancer survivor, and he’s a guy. This is his story.

After experiencing multiple struggles during his own journey toward becoming a breast cancer survivor, Bret Miller, co-founder of the Male Breast Cancer Coalition, is sharing his experiences to raise awareness and ease the burden of other men with the disease.

Preliminary recommendations made based on cases from the SOLAR-1 trial suggest that alpelisib-induced hyperglycemia can be managed with early detection, close monitoring, and prompt intervention.

For patients with early HR-positive, HER2-positive breast cancer who initiated neratinib within 1 year of completing trastuzumab and in patients who did not achieve a pathologic complete response after neoadjuvant treatment, neratinib may be a cost-effective treatment option.